Item 7.01 Regulation FD Disclosure.
On July 26, 2022, MyMD Pharmaceuticals, Inc. (the “Company”) issued a press
release announcing the completion of dosing for the first patient cohort in the
Phase 2 clinical trial of its MYMD-1® product candidate as a treatment of
chronic inflammation associated with sarcopenia/frailty in participants aged 65
years or older. A copy of the press release is furnished as Exhibit 99.1 to this
Current Report on Form 8-K and is incorporated by reference herein. The Company
undertakes no obligation to update, supplement or amend the materials attached
hereto as Exhibit 99.1.
In accordance with General Instruction B.2 of Form 8-K, the information in this
Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not
be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the “Exchange Act”), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference in
any filing under the Exchange Act or the Securities Act of 1933, as amended,
except as shall be expressly set forth by reference in such a filing.
Furthermore, the furnishing of information under Item 7.01 of this Current
Report on Form 8-K is not intended to constitute a determination by the Company
that the information contained herein, including the exhibits hereto, is
material or that the dissemination of such information is required by Regulation
FD.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit Number Description
99.1 Press Release, dated July 26, 2022 (furnished herewith pursuant
to Item 7.01)
104 Cover Page Interactive Data File (formatted as Inline XBRL)
© Edgar Online, source Glimpses
postbrexitcompliance.com 